Data and delivery: Inside AI's inventorship dilemma
Isomorphic Labs' head of IP shares why the first wave of AI-driven drug development stumbled, how data became pharma's most valuable currency, and why inventorship questions could make or break billion-dollar deals in machine learning.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
6 March 2026 With IWD approaching, WIPR urges practitioners to submit nominations for its Influential Women in IP list, recognising outstanding female leaders across the profession.
5 March 2026 The healthcare company’s chief IP counsel is researching how law firms and patent attorneys are using AI tools to inform its own guidelines for external legal providers.
5 March 2026 Moderna settles, agreeing to part with up to $2.25 billion to avoid a trial and secure a licence to continue using the platform underpinning its COVID-19 vaccine.